News | April 05, 2022
BSV strengthens women's health portfolio by acquiring Tidilan brand
It is currently available in tablet and injectable dosage forms
It is currently available in tablet and injectable dosage forms
AbbVie to present 30 abstracts demonstrating its leadership in neuroscience, including continued migraine treatment research across the spectrum of the disease, commitment to patients with advanced Parkinson's disease, and new studies in spasticity and cervical dystonia
Additional data across neurological disorders, including Alzheimer’s disease, help advance the scientific understanding of these conditions and the potential impact of early treatment
New data, including two late-breaking clinical trial presentations on mavacamten and a new analysis of the GUARD-AF study, reinforce the company’s continued commitment to those living with cardiovascular disease
These new chemical entities are covered by composition of matter patent applications. Financial terms of the deal were not disclosed
Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies
The SureSTART consumables portfolio is designed for higher performance requirements, while meeting customer budgets
Launching Dexamethasone, Azacitidine, Carboprost, and Atropine for the Institutional Market
The acquisition would enable addition of established brands with high recall amongst healthcare professionals, especially in the vitamins, minerals and supplements category
LSDCheck is CE-IVD approved LCMSMS-based testing kit for LSD in newborns
Subscribe To Our Newsletter & Stay Updated
